The evolution of pharmaceutical innovation

Knowledge Accumulation and Industry Evolution: The Case of Pharma-Biotech

Volumn , Issue , 2006, Pages 73-111

  Nightingale, Paul ^a   Mahdi, Surya ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33750107132     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511493232.003     Document Type: Chapter

References (102)

1. Adams, M. D., J. M. Kelly, and J. D. Gocayne (1991), “Complementary DNA sequencing: expressed sequence tags and the Human Genome Project,” Science, 252, 1651–6.
2. Andrade, M.A., and C. Sander (1997), “Bioinformatics: from genome data to biological knowledge,” Current Opinion in Biotechnology, 8, 675–83.
3. Beattie, J., and P. Ghazal (2003), “Post-genomics technologies: thinking beyond the hype,” Drug Discovery Today, 8 (20), 909–10.
4. Bork, P., and A. Bairoch (1996), “Go hunting in sequence databases but watch out for the traps,” Trends in Genetics, 12 (10), 425–7.
5. Botstein, D., R. L. Ehite, M. Skolnick, and R.W. Davis (1980), “Construction of a genetic linkage map in man using restriction fragment length polymorphism,” American Journal of Human Genetics, 32, 314–31.
6. Bradshaw, J. (1995), Pitfalls in Creating a Chemically Diverse Compound Screening Library, unpublished document, Glaxo, London.
7. Butte, A. (2002), “The use and analysis of micro-array data,” Nature Reviews Drug Discovery, 1, 951–60.
8. Cargill, M., D. Altshuler, and J. Ireland (1999), “Characterization of single nucleotide polymorphisms in coding regions of human genes,” Nature Genetics, 22 (3), 231–8.
9. Chakravarti, A. (1999), “Population genetics – making sense out of sequence,” Nature Genetics, 21 (1 Supplement), 56–60.
10. Chandler, A. D., Jr. (1990), Scale and Scope: The Dynamics of Industrial Capitalism, Belknap Press, Cambridge, MA.
11. Chumakov, I., P. Rigault, S. Guillou, P. Ougen, A. Billaut, G. Guasconi, P. Gervy, I. LeGall, P. Soularue, L. Grinas, L. Bougueleret, C. B. Chantelot, B. Lacroix, E. Barillot, P. Gesnouin, S. Pook, G. Vaysseix, G. Frélat, A. Schmitz, J. L. Sambucy, A. Bosch, X. Estivill, J. Weissenbach, A. Vignal, H. Riethman, D. Cox, D. Patterson, K. Gardinar, M. Hattori, Y. Sakaki, H. Ichikawa, M. Ohki, D. L. Paslier, R. Heilig, S. Antonarakis, and D. Cohen (1992), “Continuum of overlapping clones spanning the entire human chromosome 21q,” Nature, 359, 380–7.
12. Cockburn, I.M., and R. Henderson (1998), “Absorptive capacity, co-authoring behaviour, and the organization of research in drug discovery,” Journal of Industrial Economics, 46 (2), 157–82.
13. Cocket, M., N. Dracopoli, and E. Sigal (2000), “Applied genomics: integration of the technology within pharmaceutical research and development,” Current Opinion in Biotechnology, 11, 602–9.
14. Collins, F. S., and Galas D. (1993), “A new five-year plan for the U.S. Human Genome Project,” Science, 262, 11.
15. Collins, F. S., and M. S. Guyer (1995), “How is the Human Genome Project doing, and what have we learned so far?,” Proceedings of the National Academy of Sciences, 92 (24), 10841–8.
16. Collins, F. S., and V. A. McKusick (2001), “Implications of the Human Genome Project for medical science,” Journal of the American Medical Association, 285, 540–4.
17. Collins, F. S., A. Patrinos, E. Jordan, R. Gesteland, L. Walters, and members of DOE and NIH planning groups (1998), “New goals for the US Human Genome Project: 1998–2003,” Science, 282, 682–9.
18. David, P. A. (1990), “The dynamo and the computer: a historical perspective on a modern productivity paradox,” American Economic Review, 80, 355–61.
19. David, P. A. (1997), “Knowledge, property and the system dynamics of technological change,” in L. Summers and S. Shah (eds.), Proceedings of the World Bank Conference on Development Economics, World Bank, New York, 215–48.
20. David, P. A. (2004), “Understanding the emergence of open science institutions: functionalist economics in historical context,” Industrial and Corporate Change, 13 (3), 571–89.
21. Deloukas, P., G. D. Schuler, G. Gyapay, E. M. Beasley, C. Soderlund, and P. Rodriguez-Tome (1998), “A physical map of 30,000 human genes,” Science, 282, 744–6.
22. DiMasi, J. A. (1995), “Trends in drug development costs, times and risks,” Drug Information Journal, 29, 375–84.
23. Donis-Keller, H., P. Green, C. Helms, S. Cartinhour, B. Weiffenbach, K. Stephens, T. P. Keith, D. W. Bowden, D. R. Smith, and E. S. Lander (1987), “A genetic linkage map of the human genome,” Cell, 23 (51), 319–37.
24. Dosi, G., P. Llerena, and M. Sylos Labini (2005), Science–Technology– Industry Links and the “European Paradox”: Some Notes on the Dynamics of Scientific and Technological Research in Europe, Working Paper no. 2005:2, Laboratory of Economics and Management, Sant’Anna School for Advanced Studies, Pisa.
25. Dosi, G. (1982), “Technological paradigms and technological trajectories: a suggested interpretation,” Research Policy, 11, 147–62.
26. Drews, J. (2000), The Impact of Cost Containment Initiatives on Pharmaceutical R&D, Annual Lecture, Centre for Medicines Research, London.
27. Duggan, D. J., M. Bittner, Y. Chen, P. Meltzer, and J. M. Trent (1999), “Expression profiling using cDNA microarrays,” Nature Genetics, 21 (1 Supplement), 10–14.
28. Freeman, C. (1982), The Economics of Innovation, 3rd edn., Pinter, Cheltenham.
29. Freeman, C., and F. Louca (2001), As Time Goes By: The Information and Industrial Revolutions in Historical Perspective, Oxford University Press, Oxford.
30. Gelbart, W. M. (1998), “Databases in genomic research,” Science, 282, 659–661.
31. Gelbert, L. M., and R. E. Gregg (1997), “Will genetics really revolutionise the drug discovery process?,” Current Opinion in Biotechnology, 8, 669–74.
32. Geuna, A., A. Salter, and W. E. Steinmueller (2003), Science and Innovation: Rethinking the Rationale for Funding and Governance, Edward Elgar, Cheltenham.
33. Gibbons, M., C. Limoges, H. Nowotny, S. Schwartzman, P. Scott, and M. Trow (1994), The New Production of Knowledge: The Dynamics of Science and Research in Contemporary Societies, Sage Publications, London.
34. Gilbert, W. (1991), “Towards a paradigm shift in biology,” Science, 249, 99.
35. Grunstein, M., and D. S. Hogness (1975), “Colony hybridisation: a method for the isolation of cloned DNAs that contain a specific gene,” Proceedings of the National Academy of Sciences, 72, 3961–5.
36. GSK (2004), “Briefing to industrial analysts,” Glaxo SmithKline, London.
37. Henderson, R. M., L. Orsenigo, and G. Pisano (1999), “The pharmaceutical industry and the revolution in molecular biology: exploring the interactions between scientific, institutional, and organizational change,” in D. C. Mowery and R. R. Nelson (eds.), Sources of Industrial Leadership: Studies of Seven Industries, Cambridge University Press, Cambridge, 267–311.
38. Holzman, N. A., and T. M. Marteau (2000), “Will genetics revolutionize medicine?,” New England Journal of Medicine, 343, 141–4.
39. Hopkins, M. (1998), An Examination of Technology Strategies for the Integration of Bioinformatics in Pharmaceutical R&D Processes, Masters dissertation, Science and Technology Policy Research Unit, University of Sussex, Brighton.
40. Horrobin, D. F. (2001), “Realism in drug discovery – could Cassandra be right?,” Nature Biotech, 19, 1099–100.
41. Horrobin, D. F. (2003), “Modern biomedical research: an internally self-consistent universe with little contact with medical reality?,” Nature Review Drug Discovery, 2, 151–4.
42. Houston, J. G., and M. Banks (1997), “The chemical-biological interface: developments in automated and miniaturised screening technology,” Current Opinion in Biotechnology, 8, 734–40.
43. Hudson, T. J., L.D. Stein, S.S. Gerety, J. Ma, A.B. Castle, J. Silva, D.K. Slonim, R. Baptista, L. Kruglyak, and S.H. Xu (1995), “An STS-based map of the human genome,” Science, 270, 1919–20.
44. Hughes, T. (1983), Networks of Power: Electrification in Western Society, 1880–1930, Johns Hopkins Press, Baltimore.
45. Lahana, R. (1999), “How many leads from HTS?,” Drug Discovery Today, 4 (10), 447–8.
46. Lander, E. S. (1996), “The new genomics: global views of biology,” Science, 274, 536–9.
47. Lander, E. S., and N. Schork (1994), “Genetic dissection of complex diseases,” Science, 265, 2037–48.
48. Lewontin, R. C. (2000), It Ain’t Necessarily So: The Dream of the Human Genome and Other Illusions, New York Review of Books, New York.
49. Lipshutz, R. J., S. P. A. Fodor, T. R. Gingeras, and D. J. Lockhart (1999), “High-density synthetic oligo-nucleotide arrays,” Nature Genetics, 21 (1 Supplement), 20–4.
50. Mahdi, S. (2003), “Search strategy in product innovation process: theory and evidence from the evolution of agrochemical lead discovery process,” Industrial and Corporate Change, 12 (2), 235–70.
51. Martin, P. (1998), From Eugenics to Therapeutics: Science and the Social Shaping of Gene Therapy, D.Phil. thesis, Science and Technology Policy Research Unit, University of Sussex, Brighton.
52. McKelvey, M. (1995), Evolutionary Innovation: The Business of Biotechnology, Oxford University Press, Oxford.
53. Meldrum, D. R. (1995), “The interdisciplinary nature of genomics,” IEEE Engineering in Medicine and Biology, 14, 443–8.
54. Meldrum, D. R. (2000a), “Automation for genomics: part 1, preparation for sequencing,” Genome Research, 10 (8), 1081–92.
55. Meldrum, D. R. (2000b), “Automation for genomics: part 2, sequencers, micro-arrays, and future trends,” Genome Research, 10 (9), 1288–1303.
56. Mowery, D. C. (1983), “The relationship between intrafirm and contractual forms of industrial research in American manufacturing, 1900–1940,” Explorations in Economic History, 20, 351–74.
57. Murray Rust, P. (1994), “Bioinformatics and drug discovery,” Current Opinion in Biotechnology, 5, 648–53.
58. Murray, J. C., K. H. Buetow, J. L. Weber, S. Ludwigsen, T. Shirpbier- Meddem, and F. Manion (1994), “A comprehensive human linkage map with centimorgan density,” Science, 265, 2049–54.
59. Nature Genetics (1999), “The chipping forecast,” Nature Genetics, 21 (1 Supplement), 1–60.
60. Nature Genetics (2002), “The chipping forecast II,” Nature Genetics, 32 (4 Supplement), 461–552.
61. Nelson, R. R. (1991), “Why do firms differ, and how does it matter?,” Strategic Management Journal, 12 (1), 61–74.
62. Nelson, R. R. (2004), “The market economy, and the scientific commons,” Research Policy, 33 (3), 455–71.
63. Nelson, R. R., and S. G. Winter (1982), An Evolutionary Theory of Economic Change, Belknap Press, Cambridge, MA.
64. Nightingale, P. (1998), “A cognitive theory of innovation,” Research Policy, 27 (7), 689–709.
65. Nightingale, P. (2000), “Economies of scale in experimentation: knowledge and technology in pharmaceutical R&D,” Industrial and Corporate Change, 9 (2), 315–59.
66. Nightingale, P. (2004), “Technological capabilities, invisible infrastructure and the un-social construction of predictability: the overlooked fixed costs of useful research,” Research Policy, 33 (9), 1259–84.
67. Nightingale, P., T. Brady, A. Davies, and J. Hall (2003), “Capacity utilisation revisited: software, control & the growth of large technical systems,” Industrial and Corporate Change, 12 (3), 477–517.
68. Nightingale, P., and P. Martin (2004), “The myth of the biotech revolution,” Trends in Biotechnology, 22 (11), 564–9.
69. Pavitt, K. (1984), “Sectoral patterns of technological change: towards a taxonomy and a theory,” Research Policy, 13, 343–74.
70. Pavitt, K. (1998), “Technologies, products and organisation in the innovating firms: what Adam Smith tells us and Schumpeter doesn’t,” Industrial and Corporate Change, 7 (3), 433–52.
71. Pavitt, K. (1999), Technology, Management and Systems of Innovation, Edward Elgar, Cheltenham.
72. Pavitt, K. (2001), “Public policies to support basic research: what can the rest of the world learn from US theory and practice? (And what they should not learn),” Industrial and Corporate Change, 10 (3), 761–79.
73. Pennisi, E. (1998), “A closer look at SNPs suggests difficulties,” Science, 281, 1787–9.
74. Penrose, E. (1960), “The growth of the firm: a case study of the Hercules Powder Company,” Business History Review, 43, 1–23.
75. Penrose, E. 1959, The Theory of the Growth of the Firm, Basil Blackwell, Oxford.
76. Polanyi, M. (1966), The Tacit Dimension, Doubleday, New York.
77. Pollack, A. (2002), “Despite billions for discoveries, pipeline of drugs is far from full,” New York Times, C1.
78. Risch, N. J. (2000), “Searching for genetic determinants in the new millennium,” Nature, 405, 847–56.
79. Risch, N. J., and K. Merikangas (1996), “The future of genetic studies of complex human diseases,” Science, 273, 1516–17.
80. Rommens, J. M., M. C. Januzzi, and B. -S. Kerem (1989), “Identification of the cystic fibrosis gene: chromosome walking and jumping,” Science, 245, 1059–65.
81. Rosenberg, N. (1974), “Science innovation and economic growth,” Economic Journal, 84, 90–108.
82. Rosenberg, N. (1976), Perspectives on Technology, Cambridge University Press, Cambridge.
83. Rosenberg, N. (1979), “Technological interdependence in the American economy,” Technology and Culture, 20 (1), 25–40.
84. Roses, A. D. (2000), “Pharmacogenetics and the practice of medicine,” Nature, 405, 857–65.
85. Roses, A. D. (2001), “Pharmacogenetics,” HumanMolecular Genetics, 10 (20), 2261–7.
86. Rothwell, R. (1992), “Successful industrial innovation: critical factors for the 1990s,” R&D Management, 22 (3), 221–39.
87. Scherer, M. F. (1993), “Pricing, profits and technological progress in the pharmaceutical industry,” Journal of Economic Perspective, 7, 97–115.
88. Schwartzman, D. (1976), Innovation in the Pharmaceutical Industry, Johns Hopkins University Press, Baltimore.
89. Smith, L.M., S. Fung, M.W. Hunkapiller, T. J. Hunkapiller, and L. E. Hood Schwartzman, D. (1985), “The synthesis of oligonucleotides containing an aliphatic amino group at the 5’ terminus: synthesis of fluorescent DNA primers for use in DNA sequence analysis,” Nucleic Acids Research, 13, 2399–412.
90. Smith, L. M., J. Z. Sanders, R. J. Kaiser, P. Hughes, C. Dodd, C. R. Connell, C. Heiner, S. B. H. Kent, and L. E. Hood (1986), “Fluorescence detection in automated DNA sequence analysis,” Nature, 321, 674–9.
91. Southern, E. M. (1975), “Detection of specific sequences among DNA fragments separated by gel electrophoresis,” Journal of Molecular Biology, 98, 503–17.
92. Southern, E. M., K. Mir, and M. Shchepinov (1999), “Molecular interactions on microarrays,” Nature Genetics, 21 (1 Supplement), 5–9.
93. Strachan, T., and A. P. Read (2000), Human Molecular Genetics 3, Garland Press, Oxford.
94. Sudbury, P. (1999), Human Molecular Genetics, Cell and Molecular Biology in Action Series, Addison-Wesley, London.
95. Terwilliger, J. D., F. Haghighi, T. S. Hiekkalinna, and H. H. Goring (2002), “A bias-ed assessment of the use of SNPs in human complex traits,” Current Opinion in Genetics and Development, 12, 726–34.
96. Venter, C. J., S. Levy, T. Stockwell, K. Remington, and A. Halpern (2003), “Massive parallelism, randomness and genomic advances,” Nature Genetics, 33 (3 Supplement), 219–27.
97. Vincenti, W. G. (1990), What Engineers Know and How They Know It, Johns Hopkins University Press, Baltimore.
98. Wang, D. G., J. B. Fan, and C. J. Siao (1998), “Large-scale identification, mapping and genotyping of single nucleotide polymorphisms in the human genome,” Science, 280, 1077–82.
99. Weiss, K. M. (1993), Genetic Variation and Human Disease: Principles and Evolutionary Approaches, Studies in Biological Anthropology no. 11, Cambridge University Press, Cambridge.
100. Weiss, K. M., and J. D. Terwilliger (2000), “How many diseases does it take to map a gene with SNPs?,” Nature Genetics, 26 (2), 151–7.
101. Weissenbach, J., G. Gyapay, C. Dib, A. Vignal, J. Morissette, P. Millas-Seav, G. Vaysseix, and M. Lathrop (1992), “A second-generation linkage map of the human genome,” Nature, 359, 794–801.
102. Wodicka, L., H. Dong, M. Mittmann, M. H. Ho, and D. J. Lockhart (1997), “Genome-wide expression monitoring in Saccharomyces cerevisiae,” Nature Biotechnology, 15 (13), 1359–67.